Managing Diabetes by Maintaining Healthier Beta Cells: A Fresh Perspective for Diabetes Educators

Abstract

Get full access to this article

View all access options for this article.

References

Skyler

Bakris

Bonifacio

et al . Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2016;66:241-255.

Schwartz

Epstein

Corkey

Grant

Gavin

3rd Aguilar

RB.

The time is right for new classification system for diabetes mellitus: rationale and implications of the β-cell centric classification schema. Diabetes Care. 2016;39(2):179-186.

Shah

Brownlee

Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118:1808-1829.

O’Brien

Moran

Tang

et al . Patient perceptions about prediabetes and preferences for diabetes prevention. Diabetes Educ. 2016;42:667-677.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

Schwartz

Jellinger

Herman

Obviating much of the need for insulin therapy in type 2 diabetes mellitus (T2DM): a re-assessment of insulin therapy’s safety profile. Postgrad Med. 2016;128(6):609-619.

Qaseem

Barry

Humphrey

Forciea

; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(4):279-290.

Retnakaran

Kramer

Choi

et al . Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care. 2014;37(12): 3270-3278.

Armato

DeFronzo

Abdul-Ghani

Ruby

Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction. Endocr Pract. 2012;18:342-350.

10.

Abdul-Ghani

Puckett

Triplitt

et al . Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2015;17:268-275.

11.

Bloem

Chang

AM.

Short-term exercise improves beta cell function and insulin resistance in older people with impaired glucose tolerance. J Clin Endocrinol Metab. 2008;93:387-392.

12.

Chimen

Kennedy

Nirantharakumar

et al . What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55(3):542-551.

13.

Kitabchi

Temprosa

Knowler

et al . Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes. 2005;8:2404-2414.

14.

American Diabetes Association Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;S1:S159.

15.

Gomes

Tófolo

Rinaldi

et al . Moderate exercise restores pancreatic beta-cell function and autonomic nervous system activity in obese rats induced by high-fat diet. Cell Physiol Biochem. 2013;32(2):310-321.

16.

Nieuwoudt

Fealy

Foucher

et al . Functional high-intensity training improves pancreatic β-cell function in adults with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017;313(3):E314-E320.

17.

Holliday

Blannin

Appetite, food intake and gut hormone responses to intense aerobic exercise of different duration. J Endocrinol. 2017;235(3):193-205.

18.

Codella

Luzi

Inverardi

The anti-inflammatory effects of exercise in the syndromic thread of diabetes and autoimmunity. Eur Rev Med Pharmacol Sci. 2015;19(19):3709-3722.

19.

Petrenko

Saini

Giovannoni

et al . Pancreatic α- and β-cellular clocks have distinct molecular properties and impact on islet hormone secretion and gene expression. Genes Dev. 2017;31(4):383-398.

20.

Rakshit

Qian

Colwell

et al . The islet circadian clock: entrainment mechanisms, function and role in glucose homeostasis. Diabetes Obes Metab. 2015;17(1):115-122.

21.

Best

Hoogwerf

Herman

et al . Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90-95.

22.

Marso

Daniels

Brown-Frandsen

et al . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.

23.

Zinman

Wanner

Lachin

et al . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

24.

Dormandy

Charbonnel

Eckland

et al . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.

25.

Kernan

Viscoli

Furie

et al . Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321-1331.

26.

Pfeffer

Claggett

Diaz

et al . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-2257.

27.

Nissen

Nicholls

Wolski

et al ; PERISCOPE Investigators FT. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes The PERISCOPE Randomized Controlled Trial. JAMA. 2008;299(13):1561-1573.

28.

UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.

29.

Holman

Paul

Bethel

Matthews

Neil

HA.

10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.

30.

Mellbin

Malmberg

Norhammar

Wedel

Ryden

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Euro Heart J. 2008;29:166-176.

31.

Ghotbi

Kober

Finer

et al . Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes. A substudy of the SCOUT trial. Diabetes Care. 2013;36:3746-3753.

32.

Anselmino

Ohrvik

Malmberg

Standl

Ryden

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008;29:177-184.

33.

Smooke

Horwich

Fonarow

GC.

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168-174.

34.

Colayco

Niu

McCombs

Cheetham

TC.

A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011;34:77-83.

35.

Holden

Jenkins-Jones

Morgan

Schernthaner

Currie

CJ.

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015;17:350-362.

36.

Gamble

Chibrikov

Twells

et al . Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2016;5:43-52.

37.

Kiani

Boucher

Wei

et al . 2016 insulin requirement is a risk factor for end-stage renal disease (ESRD) independent of hemoglobin (Hb) A1C levels in type 2 diabetes mellitus (T2DM). Presented at American Society of Nephrology Kidney Week, Chicago, IL, 2016.

38.

Garber

Abrahamson

Barzilay

et al . AACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM–2017. https://www.aace.com/publications/algorithm. Accessed February 10, 2017.

39.

Schwartz

. Do many people with type 2 diabetes really need insulin? In: Draznin

Low Wang

Rubin

, eds. Diabetes Case Studies. Alexandria, VA: American Diabetes Association; 2015: 247-249.

40.

Schwartz

. Translating the new science of diabetes mellitus (DM): constructs for aligning the disease & its treatment with the new science of dm. Presented at the 12th Copenhagen Bioscience Conference, October 1-5, 2017, Copenhagen, Denmark.